HONG KONG SAR / DÜSSELDORF, GERMANY - Media OutReach Newswire - 20 November 2026 - Hong Kong Science and Technology Parks Corporation (HKSTP) today concluded its first-ever delegation of 22 park companies and local university partners to MEDICA 2026 from 16 to 19 November in Düsseldorf, Germany. Joining hands with the Hong Kong Trade Development Council (HKTDC), the Hong Kong MedTech Association, the delegation has advanced new partnerships between Hong Kong, Germany and Europe, while showcasing Hong Kong and the Chinese Mainland medical innovations at the world's leading trade fair for medical technology.
HKSTP concluded its first-ever delegation of 22 park companies and local university partners to MEDICA 2026 from 16 to 19 November in Düsseldorf, Germany.
Landmark MoUs were signed by HKSTP with German healthtech ecosystem leaders Medical Valley EMN and Kalms Consulting during the event. Such partnerships reinforce Hong Kong's status as a leading global hub for life and health tech innovation, offering seamless access to the Chinese Mainland's 390+ million citizens regularly using digital health services and China among the fastest-growing medical devices markets, projected to reach USD 82 billion by 2032.
The four-day event brought together global innovators to showcase technologies in surgical robotics, diagnostics, ophthalmology, rehabilitation and metabolic health. Making its debut at MEDICA, HKSTP has fostered two-way ties between Hong Kong, Germany and the Europe market empowering Chinese innovators to expand globally while opening doors for European innovators seeking access to Hong Kong, the Greater Bay Area, China and wider Asian region.
Mr Terry Wong, CEO of HKSTP, said, "Turning breakthroughs into global healthcare solutions requires deep ecosystem collaboration. At our MEDICA debut, engaging key European partners such as Medical Valley EMN and Kalms Consulting is vital to building trusted cross-border pathways for regulatory readiness and market access. Equally exciting is seeing our park companies forge commercial partnerships and debut new innovations on the global stage, demonstrating how HKSTP connects world-class R&D with international markets to create lasting impact."
Building Hong Kong-Europe Pathways for Healthcare Innovation
A key highlight at MEDICA 2026 was the signing of strategic MoUs between HKSTP and European partners. HKSTP signed an MoU with Medical Valley EMN to support market access, business matching, clinical, research and innovation opportunities, and stakeholder engagement. HKSTP also signed an MoU with Kalms Consulting to strengthen regulatory readiness and commercialisation for HKSTP companies entering European markets, spanning advisory, market access, business development and facilitating industry connections.
HKSTP also provided a platform for park companies at MEDICA to advance international partnerships and market expansion:
- Orange Biotech, a developer of low-cost CRISPR-based diagnostic testing platforms, signed an MoU with Hungarian medical device company CorLab to explore distribution of its point-of-care diagnostic products in Hungary and the wider European Union, alongside regulatory, market-access and commercialisation activities and potential future manufacturing and assembly in Hungary.
- Pushkang Biotechnology signed a strategic cooperation agreement with Egypt-based Keen Diagnostic Partners (KDP) to introduce and commercialise its MS200 Automated Chemistry Analyzer and related reagent panels in Egypt. Combining Pushkang's microfluidic platforms with KDP's local healthcare network, the partnership will drive product deployment, training, and market development, expanding access to high-quality, cost-effective diagnostics across Egyptian hospitals and clinics.
Premiering Healthcare Innovation on the Global Stage
Alongside new partnerships, HKSTP park companies unveiled new healthcare technologies to global audiences at MEDICA:
- AusMed Global has marked the European soft launch of KetoMetrics®, a CE-marked device and the world's first portable, real-time breath ketone monitoring system delivering accuracy comparable to laboratory Gas Chromatography gold-standard testing. Designed for versatile deployment, KetoMetrics® empowers users in both point-of-care and home settings with quantitative metabolic insights to support weight management, wellness, sports performance, healthy ageing, and ketogenic interventions.
- Dymind has launched its upgraded, CE-marked DH-8000 haematology analysis workstation. Designed for large laboratories, this new premier analyser offers CBC, CRP, SAA and ESR testing, with expandable SPS and slide maker modules to boost efficiency.
Accelerating Two-Way MedTech Expansion Between Europe and Asia
HKSTP brought together global healthcare leaders to explore practical pathways for cross-border expansion. Speaking at MEDICA's Market Entry Stage under the theme "Unlocking Asia's Growth – Hong Kong and HKSTP as the Launchpad for Life & Health Tech". Mr Terry Wong spotlighted Hong Kong's research strengths, clinical resources, and ecosystem as an ideal gateway for global innovators entering Asia.
To deepen Asia-Europe ties, HKSTP co-hosted an executive roundtable with global law firm Clifford Chance on MedTech collaboration, alongside delegation visits to Siemens Healthineers, Würth Group, TUM Venture Labs, and SGS Germany GmbH. These engagements sparked vital dialogue on regulation, commercialisation, investment, and two-way market access.
HKSTP curated targeted business matching sessions with industry leaders including Deloitte, DQS, High-Tech Gründerfonds, Intertek, Kalms Consulting, SGS, and Tekno Surgical to foster valuable connections and potential collaboration with ecosystem partners across Europe.
Global Recognition for Hong Kong Life and Health Technology
HKSTP's life science companies continue to earn top international recognition across major global biotech competitions. At BioJapan 2026, Excalipoint Therapeutics and GenEditBio took first and second place at the SHIC Fast Track. In the US, OncoImmunostics, Advanced Micro Integrations, and Rare Power captured the Grand, Gold, and Silver awards at the 2026 Washington Innovation & Entrepreneurship Competition. These wins confirm Hong Kong's ventures are clinically validated, investment-ready, and primed for global healthcare breakthroughs.
HKSTP supports more than 400 Life and Health Technology companies within an ecosystem. Through funding, incubation programmes, infrastructure and industry connections, HKSTP supports innovators from R&D and validation through to commercialisation and international expansion.
Appendix: MEDICA 2027 – List of 22 exhibitors at Hong Kong Pavilion including park companies outside the Hong Kong Pavilion (in alphabetical order)
- Agilis Robotics Limited
- AusMed Global Limited
- Baptist University
- b-One Ortho (Hong Kong) Limited
- Chinese University of Hong Kong
- Hong Kong Dymind Biological Co., Limited
- Eyebright Medical Technology (Hong Kong) Limited
- HongKong Hugemed Holding Co., Limited
- Hong Kong Polytechnic University
- Hopebotics Limited
- iBone Healthcare Limited
- Kulia Labs HK Limited
- Lasmx Trade Limited
- MagMint Scientific Limited
- Multera Limited
- NeurOssence Bio Limited
- Okosix (Ecotec Global Limited)
- Orange Biotech Limited
- Pushkang Biotechnology Limited
- University of Hong Kong, Department of Orthopaedics and Traumatology
- Wondfo Biotech (HK) Co., Limited
- Yuanhua Robotics, Perception & AI Technologies (HK) Limited
Hashtag: #HKSTP
The issuer is solely responsible for the content of this announcement.
Hong Kong Science and Technology Parks Corporation
Hong Kong Science and Technology Parks Corporation (HKSTP) was established in 2001 and has built a proven foundation as Hong Kong's leading innovation and technology (I&T) ecosystem. Established for 25 years, HKSTP is supporting 14 unicorns, has nurtured more than 17,000 research professionals and built a community of over 2,500 technology companies from 26 countries and regions across four strategic technology clusters: Life and Health Technology, AI and Data Science, Microelectronics and Advanced Manufacturing, and GreenTech and New Energy.
As an ecosystem orchestrator, HKSTP provides end-to-end support to attract and nurture talent, accelerate commercialisation and help technology ventures scale. Its innovation infrastructure spans over 240 hectares covering Hong Kong Science Park in Pak Shek Kok, InnoCentre in Kowloon Tong, and three modern InnoParks in Tai Po, Tseung Kwan O and Yuen Long, advancing Hong Kong's vision for new industrialisation and smart manufacturing.
Hong Kong Science Park Shenzhen Branch in Futian, Shenzhen, strengthens cross-border collaboration by connecting Hong Kong, the Chinese Mainland and global innovation networks and propels Chinese innovators onto the world stage, while also delivering comprehensive GBA landing support to accelerate cross-border success for local and international ventures.
As HKSTP enters its next chapter with strong foundations, it continues to deepen impact, elevate quality and create value for innovators. As an ecosystem built to lead change, HKSTP is empowering Hong Kong to define what comes next in innovation, growth and opportunity.
More information about HKSTP is available at www.hkstp.org.
** This press release is distributed by Media OutReach Newswire through automated distribution system, for which the client assumes full responsibility. **
Revenue Growth Accelerates; Operating Profit Increases Substantially
HONG KONG SAR – Media OutReach Newswire – 20 November 2026 – Phancy Group Co., Ltd. ("Phancy" or "the Group", stock code: 6682.HK), a leading full-stack enterprise-AI cloud services platform, today announced its business performance for the nine months ended September 30, 2026 ("the period").
During the period, the Group recorded an acceleration in revenue growth across its businesses and a substantial increase in operating profit. The Group achieved revenue of RMB6,747 million, up 53.3% year on year. Gross profit amounted to approximately RMB2,260 million, up 39.4% year on year, representing a notable acceleration from the same period last year. Overall gross profit margin stood at approximately 33.5%, a steady improvement from the first half of the year. The Group's revenue growth was accelerated by rising enterprise demand for more efficient AI resource management and the deployment of large model inference across a wider range of business scenarios.
The Group further optimized its cost structure. In the first nine months of 2026, its operating expense ratio declined by more than two percentage points compared with the first half of the year. Operating cash flow improved significantly, and the cash collection cycle shortened significantly. The Group's overall financial leverage remained low, and the cost of its RMB-denominated borrowings in the third quarter decreased to 2.25% to 2.80%, reflecting a sound financial position.
Dr. Dai Wenyuan, Founder, Chairman and Chief Executive Officer of Phancy, said, "In the first nine months of the year, revenue growth accelerated across the Group's businesses, operating profit increased substantially and profitability improved further. For Phancy, high-quality growth is not only about expanding scale, but also about building sustainable profitability. Enterprise demand for AI is eevolving. Clients need not only more capable models, but also better management of computing power and models, so that AI can operate efficiently and reliably in real business settings. As AI reaches more industries, the next priority is to strengthen the infrastructure that supports its development and operation. . Over the past 12 years, we have worked to bring AI to more people. Looking ahead, we want to enable more people to contribute to making AI better, so that better AI can truly improve people's lives. This is the thinking behind the new vision we introduced on our 12th anniversary: 'Everyone for AI'."
AI Platform Delivers Strong Growth and Steadily Improving Profitability
In the first nine months of 2026, the AI Platform business recorded revenue of RMB5,392 million, up 32.0% year on year. Its gross profit margin improved steadily in the third quarter compared with the first half of the year. As of September 30, 2026, the business' orders on hand amounted to approximately RMB9 billion, representing significant growth both year on year and quarter on quarter.
AI Platform is the Group's main revenue contributor and operates under an asset-light model. The business accelerated growth while further improving profitability and continuing to expand its market share. As clients place greater emphasis on AI sovereignty, data security, and internal control and governance, the Group remains confident in the business's long-term growth prospects.
During the period, Phancy continued to enhance the capabilities of its AI Platform products. In computing resource management, the Group uses technologies including HAMi vGPU to schedule heterogeneous computing resources. Launched in October, subsequent to the period, ModelSphere further covers model adaptation, inference performance optimization, and Token management and scheduling, helping clients use their existing resources more efficiently and reduce the cost of deploying and operating AI applications. Customer stickiness continues to increase alongside improvements in product capabilities.
API Business Sustains Rapid Growth with Further Gross Margin Improvement
In the first nine months of 2026, the API business recorded revenue of RMB1,014 million, up 1,556% year on year. Building on the year-on-year improvement in its gross profit margin in the first half of 2026, the API business's gross profit margin continued to achieve significant improvement in the third quarter compared with the first half.
As client demand for Tokens continued to grow, the Group also focused on the operational efficiency and resource utilization of the API business. As of September 30, 2026, the available computing power resources for the API business increased to 40,000 PFLOPS, an increase of 42.9% from the end of the first half of the year.
With client demand for Tokens remaining strong and the API business's financing costs remaining at a low level, the API business is expected to sustain its growth, and its profit margin is expected to improve further.
From a business portfolio perspective, the AI Platform business continues to deliver high-quality growth on an asset-light model, while the API business serves fast-growing demand for model inference. The two businesses complement each other operationally and financially, laying a solid foundation for the Group's long-term, steady growth and continued improvement in profitability.
Enhancing Enterprise AI Resource Management and Expanding the Model Portfolio
The Group continued to advance core product iteration and technology capabilities around the key needs of enterprise AI adoption.
In September 2026, Phancy was included in the first batch of enterprises publicly announced by the Ministry of Industry and Information Technology (MIIT) for development as demonstration enterprises of the National Emerging Industry Development Demonstration Bases, one of 18 enterprises nationwide selected in the first batch. In addition, Phancy ranked first overall in the China AI Computing Power Management Platform Technical Capability Assessment, 2026, published by International Data Corporation (IDC) in September. It was also the only vendor to receive full marks across all four dimensions: compute resource management, compute operations, technical architecture and delivery services.
In model development, subsequent to the period, Phancy launched its Phai series of models in November, comprising Phai-A1, a general-purpose language model, and Phai-M1, a video generation model. Phancy plans to make the weights for both models available to developers worldwide in the near future. Phai-A1 is designed for applications such as software development and AI assistants, with a focus on efficient inference and long-context processing. It supports a one-million-token context window and can be deployed locally on a personal computer. Phai-M1 is designed for live-action film and television content and AI-generated short-form dramas, with a focus on improving visual detail and synchronizing visuals with audio.
Phancy also completed end-to-end post-training of Phai-A1 on a leading domestic compute platform, including reinforcement learning, enabling close integration between model training and the platform. This makes Phancy one of the few enterprises in China to have completed the full post-training process, including reinforcement learning, on that platform. The achievement further demonstrates the Group's capabilities in developing in-house models, integrating them with domestic compute platforms and deploying enterprise AI technologies.
Outlook: From "AI for Everyone" to "Everyone for AI"
In November 2026, Phancy introduced its new vision "Everyone for AI" on its 12th anniversary. Over the past 12 years, Phancy has brought AI to various industries and more people. As the adoption of large models and AI agents accelerates and AI applications become more widespread, the infrastructure that supports the development and operation of AI has become increasingly important.
Looking ahead, Phancy will continue to deepen its commitment to AI infrastructure, addressing critical bottlenecks in AI development and operation and enabling broader deployment of AI applications through continued infrastructure improvements. Moving from helping more people use AI to making AI better, Phancy aims to work with partners and the wider AI community to build a stronger foundation for AI development—so that more efficient, more trustworthy AI can better serve people and improve their lives.
Hashtag: #Phancy
https://phai.phanthy.com
The issuer is solely responsible for the content of this announcement.
About Phancy Group
Phancy Group (6682.HK) is a leading full-stack AI cloud services platform, providing comprehensive solutions for the AI 2.0 era. Our offerings include SageAIOS, HAMi vGPU and ModelHub XC, delivering efficient and scalable AI infrastructure with end-to-end capabilities. We provide a complete solution from heterogeneous compute resource management and optimization to the deployment of intelligent agent models. These solutions empower digital transformation across a wide range of industries, supporting our vision of building a large-scale and efficient "Token Factory."
Guided by the vision of "Everyone for AI," Phancy Group is committed to bringing together more technologies, enterprises and developers to advance AI together.
** This press release is distributed by Media OutReach Newswire through automated distribution system, for which the client assumes full responsibility. **